BioWorld - Sunday, June 14, 2026
Breaking News: Ongoing coverage of the Ebola outbreakBreaking News: Viva in vivo! At EHA, in vivo CAR T data continues to impressBreaking News: Ongoing coverage of the Ebola outbreak

BioWorld Science
BioWorld Science RSS Feed RSS

Antibodies illustration
Neurology/psychiatric

Anti-CX3CR1 antibody prevents disease severity in multiple sclerosis model

Sep. 19, 2024
Secondary progressive multiple sclerosis (SPMS) is a chronic form of disease that occurs after relapsing-remitting MS, with a progressive disease course, and its pathogenesis remains unclear. CX3C chemokine receptor 1 (CX3CR1) is a G protein-coupled receptor that may be a useful marker of Eomes+ Th cells; the antigen has been shown to be expressed by cytotoxic Th cells and required for late-onset disease.
Read More
Heart, DNA and ECG
Cardiovascular

Nanovation Therapeutics partners with Novo Nordisk on genetic medicines for cardiometabolic and rare diseases

Sep. 19, 2024
Nanovation Therapeutics Inc. has established a multiyear partnership with Novo Nordisk A/S to advance the development of novel genetic medicines targeting cardiometabolic and rare diseases. The partnership brings together Nanovation’s proprietary long-circulating lipid nanoparticle (lcLNP) technology for RNA delivery to cells outside of the liver, and Novo Nordisk’s expertise in cardiometabolic and rare disease R&D and clinical translation.
Read More
Endocrine/metabolic

Targeting PTP1B prevents olanzapine-induced metabolic comorbidities

Sep. 19, 2024
Previous research has demonstrated that patients treated with the second-generation antipsychotic olanzapine (OLA) have metabolic dysfunctions and insulin resistance. Researchers from Instituto de Investigaciones Biomedicas “Alberto Sols” and collaborators investigated the impact of intraperitoneal (i.p.) OLA treatment on peripheral insulin sensitivity as well as potential effects of inhibiting the protein tyrosine phosphatase 1B (PTP1B), a negative regulator of insulin signaling.
Read More
Brain waves
Neurology/psychiatric

ECTRIMS 2024: Time for neuroprotection

Sep. 19, 2024
By Coia Dulsat
The Annual Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) meeting in Copenhagen this week is celebrating its 40th edition. In recognition of this landmark, the plenary session and opening lecture were attended by Queen Margrethe of Denmark. Afterward, the hot topic session on neuroprotective therapies set the stage for the subsequent discussions on the latest trends in the management and treatment of multiple sclerosis (MS).
Read More